Advertisement

Topics

Oxford BioMedica Company Profile

11:47 EST 23rd November 2017 | BioPortfolio

Oxford BioMedica advanced gene therapy techniques.

Location

Robert Robertson AvenueThe Oxford Science Park
Oxford
Oxfordshire
OX4 4 GA
United Kingdom

Contact

Phone: +44 1865 783 000
Fax: +44 1865 783 001
Email: p.nolan@oxfordbiomedica.co.uk


News Articles [306 Associated News Articles listed on BioPortfolio]

Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrate...

Oxford BioMedica inks $100 million supply agreement

Oxford BioMedica has signed an agreement for the commercial and clinical supply of lentiviral vectors…

Oxford BioMedica (OXB) - Kymriah approved - royalties to OXB assured

Edison Investment Research - Pharmaceutical & healthcare - Oxford BioMedica: Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been ...

Oxford BioMedica secures commercial supply licence from UK MHRA

Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material...

Oxford BioMedica signs $100m CAR-T deal with Novartis

Oxford BioMedica has signed a deal worth up to $100m with Novartis to supply modified viruses used to generate its CAR-T therapies. The deal represents a major financial boost for the UK biotech fir...

Oxford BioMedica could get $100m following CAR-T approval

UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ c...

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with materia...

Drugs and Medications [0 Results]

None

Clinical Trials [72 Associated Clinical Trials listed on BioPortfolio]

Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types

The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...

A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System

The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...

Oxford® Partial Knee Kinematics Gait Analysis Study

The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...

Outcome Analysis of the Oxford Partial Knee Arthroplasty

Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty

A Clinical Investigation of the Oxford® Partial Knee System

The purpose of this prospective data collection is to document the performance and clinical outcomes of the Oxford® Partial Knee System.

Companies [105 Associated Companies listed on BioPortfolio]

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was esta...

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Oxford Resource Partners, LP

Oxford Resource Partners, LP is a low cost producer of high value steam coal in Northern Appalachia and the Illinois Basin. Oxford markets its coal primarily to large electric utilities with coal-fir...

Oxford Healthcare Technology

Oxford Healthcare Technology is a staffing firm that leverages their recruiting expertise to deliver experienced healthcare professionals and project teams for consulting engageme...

More Information about "Oxford BioMedica" on BioPortfolio

We have published hundreds of Oxford BioMedica news stories on BioPortfolio along with dozens of Oxford BioMedica Clinical Trials and PubMed Articles about Oxford BioMedica for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford BioMedica Companies in our database. You can also find out about relevant Oxford BioMedica Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record